NCT05201911已完成1 期
A Single Arm, Single Dose Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Select Organs in Patients With Systemic Amyloidosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- To measure the tissue distribution of 124I-AT-03 in select organs in patients with systemic amyloidosis as shown in the Positron Emission Tomography/Computed Tomography (PET/CT scans) series.
研究概览
简要总结
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
详细描述
Eligible subjects will receive a single dose of radiolabeled AT-03, a fusion protein of serum amyloid P and a single chain Fc receptor. Repeat Positron Emission Tomography/Computed Tomography (PET/CT) scans will be performed over a ~7 day period to assess the biodistribution of AT-03 to amyloid-containing tissues in patients with systemic amyloidosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understands the study procedures and capable of giving signed informed consent, as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Male or female ≥18 years of age.
- •Has a confirmed diagnosis of Amyloid Light-Chain (AL), Transthyretin Amyloidosis (ATTR), or Leukocyte chemotactic factor 2 amyloidosi (ALECT2), or any other forms of systemic amyloidosis based on any one of the following:
- •a histologic confirmation with a biopsy containing deposits of apple-green birefringent, congophilic material;
- •genetic screening with presence of amyloid-related pathology; and/or
- •amyloid-specific imaging study.
- •Has known involvement of at least one thoracoabdominal organ (excluding peripheral nervous system) by clinical history (e.g., imaging consistent with amyloid deposition, organ biopsy, elevated amyloid-related biomarkers, etc.).
- •For women of childbearing potential: agreement to remain as abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 90 days after the last dose of study intervention.
- •A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
- •Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices.
- •Contraception methods that do not result in a failure rate of <1% per year such as cap, diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable.
- •The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm, as defined below:
- •With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 30 days plus 90 days (a spermatogenesis cycle) after the last dose of study intervention. Men must refrain from donating sperm during this same time period.
排除标准
- •Is pregnant or breast-feeding.
- •Is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis.
- •Has participated in another nuclear medicine amyloid imaging clinical trial protocol and received tracer injection in the 4 months prior to Screening.
- •Has a significant co-morbidity (e.g., ECOG score of 3 or greater), NYHA Class IV heart failure, uncontrolled infection, or other ongoing serious illness.
- •Has a known allergy to iOSAT iodine treatment.
- •Has end-stage renal disease and is receiving hemodialysis or peritoneal dialysis.
- •Has received an investigational agent within five half-lives of the agent or 30 days, whichever is longer, prior to Screening.
- •Has any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.
研究组 & 干预措施
Injection of I-124 AT03.
Experimental
Single arm only, no placebo or comparator
干预措施: 124I-AT03 (Drug)
结局指标
主要结局
To measure the tissue distribution of 124I-AT-03 in select organs in patients with systemic amyloidosis as shown in the Positron Emission Tomography/Computed Tomography (PET/CT scans) series.
时间窗: Day 6.
Visual determination of 124I-AT-03 uptake in the heart, kidneys, liver and spleen (positive or negative) at Days 4 and 6.
次要结局
- Number of participants with treatment-related adverse events.(Assessed from time of consent through the day 28 follow-up phone call.)
- Number of participants with abnormal laboratory test results.(Assessed from time of consent through Day 6.)
- Whole blood radioactivity of 124I-AT-03 in subjects with systemic amyloidosis.(Days 1, 4, and 6.)
- Selected tissue-bound half-life of 124I-AT-03 in subjects with systemic amyloidosis.(Days 4 and 6.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the SkeletonMetastasesPharmacokineticsProstate CancerNCT00748046Bayer10
已完成
1 期
A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male VolunteersHealthyNCT01756768Pfizer6
已完成
1 期
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersMesotheliomaOvarian CancerPancreatic CancerNon-small Cell Lung CancerNCT01521325Morphotek6
已完成
1 期
A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart FailureHeart FailureNCT00891241Lantheus Medical Imaging12
撤回
1 期
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult ParticipantsHealthyNCT04712006Janssen Research & Development, LLC